Amivantamab plus lazertinib shows survival benefit in lung cancer - PharmaTimes Janssen drug combination extends life expectancy during trial

#oncology #Amivantamab #lazertinib #lungcancer #Janssen #phase3clinicaltrial #MARIPOSAstudy #EGFRmutatedadvancednonsmallcelllungcancer #NSCLC #nonsmallcelllungcancer #Rybrevant #Lazcluze #EuropeanLungCancerCongress #lungcancertreatment #patientoutcomes
pharmatimes.com/news/amivant...

Eric K. Singhi: Does MARIPOSA study update simplify first-line treatment decisions? - OncoDaily Eric K. Singhi: Does MARIPOSA study update simplify first-line treatment decisions? / cancer, combination therapy, Eric K. Singhi, MARIPOSA study, MD Anderson

Does MARIPOSA study update simplify first-line treatment decisions? - Eric K. Singhi
@lungoncdoc.bsky.social
@mdanderson.bsky.social

oncodaily.com/insight/eric...

#Cancer #CombinationTherapy #MARIPOSAstudy #OncoDaily #Oncology #Osimertinib #Medicine #Health

EC approves Rybrevant with Lazcluze for advanced lung cancer - PharmaTimes New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC

#Rybrevant #amivantamab #Lazcluze #lazertinib #advancedlungcancer #lungcancer #EGFRmutatedNSCLC #JanssenCilagInternational #advancednonsmallcelllungcancer #NSCLC #nonsmallcelllungcancer #thoraciccancer #EGFRmutationpositiveNSCLC #precisionmedicine #MARIPOSAstudy
pharmatimes.com/news/europea...